Loading clinical trials...

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects With Papillary Renal-Cell Carcinoma

NCT00726323•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically confirmed diagnosis of PRC with metastatic disease or bilateral multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance status of \</= 2.
•Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.

Exclusion Criteria

•Radiation to \>/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior anti-cancer therapy, received prior treatment with a c-met inhibitor, brain metastases,
•Any uncontrolled intercurrent illness,
•Pregnant or breastfeeding,
•HIV positive

Locations (12)

GSK Investigational Site

Greenbrae, California, United States

GSK Investigational Site

San Francisco, California, United States

GSK Investigational Site

Stanford, California, United States

GSK Investigational Site

Indianapolis, Indiana, United States

GSK Investigational Site

Bethesda, Maryland, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Detroit, Michigan, United States

GSK Investigational Site

New Brunswick, New Jersey, United States

GSK Investigational Site

Cleveland, Ohio, United States

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

June 30, 2006

Primary Completion Date

August 18, 2010

Completion Date

August 18, 2010

Last Updated

December 11, 2017

Enrollment

ACTUAL participants

Conditions

Carcinoma, Renal Cell

Interventions

foretinib (formerly GSK1363089 or XL880)

DRUG

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415

Carcinoma, Renal CellAdvanced Renal Cell Carcinoma+11 more

View study

RECRUITINGPHASE2

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824

Carcinoma, Renal Cell

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 11, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Autologous Dendritic Cell Vaccine in Kidney Cancer

A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment